2025年美国心脏协会科学年会前瞻：华东医药DR10624荣登开场报告 二期临床数据全球首发

Core Viewpoint - The announcement by East China Pharmaceutical Co., Ltd. regarding its subsidiary Zhejiang Daor Biotechnology Co., Ltd.'s innovative long-acting triple agonist DR10624 for treating severe hypertriglyceridemia has been recognized as a groundbreaking clinical trial, set to be presented at the AHA 2025 conference [1][2]. Group 1 - The DR10624-201 study results have been selected for presentation at the AHA 2025, highlighting the scientific value and clinical prospects of DR10624 [1]. - The AHA 2025 conference will take place from November 7 to 10, 2025, in New Orleans, Louisiana, and is a premier event for showcasing the latest research in cardiovascular diseases [1]. - The study's lead researcher, Professor Li Jianping, will present the clinical data for the first time at the AHA annual meeting, marking a historic breakthrough for Chinese scholars in the field of cardiovascular research [2]. Group 2 - DR10624 is a first-in-class long-acting triple-target agonist, uniquely targeting FGFR1c/Klothoβ, GLP-1R, and GCGR, and is currently the fastest-developing FGF21 triple-target drug [2]. - The drug is also undergoing a Phase II clinical study in China for treating metabolic-associated fatty liver disease with high risk of liver fibrosis, with the first subject expected to be enrolled by April 2025 [2].